Hofseth Biocare ASA

JON OLAV ØDEGÅRD APPOINTED NEW CEO OF HBC - Seite 2

Roger Hofseth said: "I have thoroughly enjoyed my past five years as a CEO of Hofseth BioCare. As the Company progresses through the exciting next steps in parallel with the strong and very positive development in Hofseth International, which will be of great importance for HBC going forward, it is a natural time for me to hand over to Jon who can concentrate fully on HBC's further development. I can then concentrate fully on securing vast amounts of fresh salmon off-cuts from our business in Hofseth International. I will, however, keenly join the Board if the General Assembly appoints me."

For further information, please contact:

Kristin Fjellby Grung
Chair of the Board of Hofseth BioCare ASA
Phone: [phone]
Email: [e-mail]  

About Hofseth BioCare ASA:

HBC is a Norwegian consumer and pet health ingredient supplier and an incubator for new drug leads. Research is ongoing to identify the individual elements within its ingredients that modulate inflammation and the immune response with pre-clinical studies in multiple clinics and university research labs in several countries. Lead clinical and pre-clinical candidates are focused on developing an oral pharmaceutical lead program to treat inflammatory disease driven by eosinophils. Preclinical trial work with the oil is ongoing to ameliorate lung inflammation in eosinophilic asthma and COPD ("smokers lung") as well as clinical work in COVID. Other leads are focused on the protection of the Gastro-Intestinal (GI) system against inflammation (including ulcerative colitis and the orphan condition necrotising enterocolitis) and using peptide fractions of salmon protein hydrolysate (SPH also known as 'ProGo') as a Medical Food to help treat age-related Sarcopenia, and as a treatment for Iron Deficiency Anemia.
The company is founded on the core values of sustainability, optimal utilization of natural resources and full traceability. Through an innovative hydrolysis technology, HBC can preserve the quality of lipids, proteins and calcium from fresh salmon off-cuts.
Hofseth BioCare's headquarters are in Ålesund, Norway with branches in Oslo, London, Zürich, New Jersey, and Palo Alto.

This information is considered to be inside information pursuant to the EU Market Abuse Regulation and is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. The stock exchange announcement was published by Jon Olav Ødegård, CEO of Hofseth BioCare ASA, at the date and time as set out above.